利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.023 秒)

    CRYO-FIXATION CARDIAC PACEMAKER LEAD EXTRACTION DEVICE
    1.
    发明申请
    CRYO-FIXATION CARDIAC PACEMAKER LEAD EXTRACTION DEVICE 审中-公开

    公开(公告)号：US20190142495A1

    公开(公告)日：2019-05-16

    申请号：US16185577

    申请日：2018-11-09

    申请人： THE CLEVELAND CLINIC FOUNDATION ,  CPSI Holdings, LLC

    发明人： Oussama Wazni ,  Marwane Berrada-Sounni ,  John M. Baust ,  Kristi K. Snyder

    IPC分类号： A61B18/02 ,  A61N1/05 ,  A61B17/3205

    摘要： A cryo-fixation lead extraction device includes a lead extraction catheter having longitudinally spaced proximal and distal catheter ends and an elongate catheter lumen. A liner has longitudinally spaced proximal and distal liner ends and an elongate liner lumen. The liner lumen is configured to selectively accept at least part of a lead being extracted longitudinally therethrough. At least a portion of the liner is located circumferentially within and/or circumferentially surrounding the catheter lumen. At least one cryogen supply line extends longitudinally through at least a portion of the liner lumen. The cryogen supply line is configured to place a cryogen fluid source into fluid communication with the distal liner end. The cryogen supply line is configured to selectively generate a patient tissue cooled zone adjacent the distal catheter end. A method of cryo-fixation lead extraction is also provided.

    CRYO-MEDICAL INJECTION DEVICE AND METHOD OF USE
    6.
    发明申请
    CRYO-MEDICAL INJECTION DEVICE AND METHOD OF USE 有权
    CRYO医疗注射装置及其使用方法

    公开(公告)号：US20130079761A1

    公开(公告)日：2013-03-28

    申请号：US13683140

    申请日：2012-11-21

    申请人： CPSI HOLDINGS LLC

    发明人： John M. Baust ,  John G. Baust ,  Anthony T. Robilotto ,  Kristi K. Snyder ,  Robert G. Van Buskirk

    IPC分类号： A61B18/02

    CPC分类号： A61B18/02 ,  A61B2018/0212 ,  A61K9/0024 ,  A61K9/145 ,  A61K31/00 ,  A61K31/282 ,  A61K31/337 ,  A61K31/513 ,  A61K31/59 ,  A61K31/7048 ,  A61K45/06 ,  A61M5/44 ,  A61M37/0069 ,  A61M2205/3606

    摘要： The resorbable cryoprobe device and process is a novel approach for treating localized disease allowing for the precise combined application of freezing temperatures and cytotoxic or cryosensitizing agents within a self-contained matrix/package for optimized tissue destruction. The cryopellet is comprised of a list of components including a source of cryogen to produce the sub-zero temperatures, a porous matrix to contain the cytotoxic agent, cytotoxic agent, and a delivery packet. Data presented herein demonstrates the efficacy of this approach in destroying cancerous tissue. For example, the application of freezing temperatures to −10° C. results in approximately 15% cell death, while exposure to cytotoxic agents such as TRAIL produces minimal cell death. The utilization of the cryopellet approach results in a synergistic effect yielding complete cell death at the same temperature. The innovation behind the resorbable probe application includes the strategic combination of agents to activate intrinsic or extrinsic cell death responses (including apoptosis and necrosis), unique packaging of the cryogen and cytotoxic agent, and a unique delivery system. The resorbable cryoprobe technology will assist directly in the treatment of cancer, as well as will likely lead to broader application for disease treatment.

    摘要翻译： 可再吸收的冷冻探针装置和方法是用于治疗局部疾病的新方法，其允许在自包含的基质/包装内精确地联合应用冷冻温度和细胞毒性或冷冻敏化剂以优化组织破坏。 冷冻条由包括产生低于零温度的冷冻源的组分的列表组成，含有细胞毒剂，细胞毒性剂和递送包的多孔基质。 本文提供的数据显示了这种方法在破坏癌组织中的功效。 例如，将冻结温度施加到-10℃导致约15％的细胞死亡，而暴露于细胞毒性剂如TRAIL的细胞会导致最小的细胞死亡。 cryopellet方法的利用导致在相同温度下产生完全细胞死亡的协同效应。 可再吸收探针应用的创新包括激活内在或外在细胞死亡反应（包括细胞凋亡和坏死），冷冻剂和细胞毒性剂的独特包装以及独特的递送系统的药剂的战略组合。 可再吸收的冷冻探针技术将有助于直接治疗癌症，并可能导致更广泛的疾病治疗应用。

    PRE- AND POST-STORAGE STRESS RESPONSE CONDITIONING
    7.
    发明申请
    PRE- AND POST-STORAGE STRESS RESPONSE CONDITIONING 审中-公开

    公开(公告)号：US20180368393A1

    公开(公告)日：2018-12-27

    申请号：US16019072

    申请日：2018-06-26

    申请人： CPSI HOLDINGS LLC

    发明人： John M. Baust ,  Kristi K. Snyder ,  Robert G. VanBuskirk

    IPC分类号： A01N1/02

    摘要： Disclosed herein are conditioning media, supplements for addition to culture or other type of media, and methods for conditioning biological samples before, after, or both before and after preservation for improved recovery outcomes, e.g., cell survival and repopulation. Also disclosed herein are cryoprotective agents and solutions or media containing cryoprotective agents for preservation of biological samples with improved recovery outcomes.

    Cryotreatment pellet
    8.
    发明授权
    Cryotreatment pellet 有权
    冷冻沉淀

    公开(公告)号：US08747397B2

    公开(公告)日：2014-06-10

    申请号：US13683140

    申请日：2012-11-21

    申请人： CPSI Holdings LLC

    发明人： John M. Baust ,  John G. Baust ,  Anthony T. Robilotto ,  Kristi K. Snyder ,  Robert G. Van Buskirk

    IPC分类号： A61B18/02

    CPC分类号： A61B18/02 ,  A61B2018/0212 ,  A61K9/0024 ,  A61K9/145 ,  A61K31/00 ,  A61K31/282 ,  A61K31/337 ,  A61K31/513 ,  A61K31/59 ,  A61K31/7048 ,  A61K45/06 ,  A61M5/44 ,  A61M37/0069 ,  A61M2205/3606

    摘要： The resorbable cryoprobe device and process is a novel approach for treating localized disease allowing for the precise combined application of freezing temperatures and cytotoxic or cryosensitizing agents within a self-contained matrix/package for optimized tissue destruction. The cryopellet is comprised of a list of components including a source of cryogen to produce the sub-zero temperatures, a porous matrix to contain the cytotoxic agent, cytotoxic agent, and a delivery packet. Data presented herein demonstrates the efficacy of this approach in destroying cancerous tissue. For example, the application of freezing temperatures to −10° C. results in approximately 15% cell death, while exposure to cytotoxic agents such as TRAIL produces minimal cell death. The utilization of the cryopellet approach results in a synergistic effect yielding complete cell death at the same temperature. The innovation behind the resorbable probe application includes the strategic combination of agents to activate intrinsic or extrinsic cell death responses (including apoptosis and necrosis), unique packaging of the cryogen and cytotoxic agent, and a unique delivery system. The resorbable cryoprobe technology will assist directly in the treatment of cancer, as well as will likely lead to broader application for disease treatment.

    摘要翻译： 可再吸收的冷冻探针装置和方法是用于治疗局部疾病的新方法，其允许在自包含的基质/包装内精确地联合应用冷冻温度和细胞毒性或冷冻敏化剂以优化组织破坏。 冷冻条由包括产生低于零温度的冷冻源的组分的列表组成，含有细胞毒剂，细胞毒性剂和递送包的多孔基质。 本文提供的数据显示了这种方法在破坏癌组织中的功效。 例如，将冻结温度施加到-10℃导致约15％的细胞死亡，而暴露于细胞毒性剂如TRAIL的细胞会导致最小的细胞死亡。 cryopellet方法的利用导致在相同温度下产生完全细胞死亡的协同效应。 可再吸收探针应用的创新包括激活内在或外在细胞死亡反应（包括细胞凋亡和坏死），冷冻剂和细胞毒性剂的独特包装以及独特的递送系统的药剂的战略组合。 可再吸收的冷冻探针技术将有助于直接治疗癌症，并可能导致更广泛的疾病治疗应用。

    Tissue engineered model
    9.
    发明授权
    Tissue engineered model 有权
    组织工程模型

    公开(公告)号：US09213025B2

    公开(公告)日：2015-12-15

    申请号：US14206533

    申请日：2014-03-12

    申请人： CPSI HOLDINGS LLC

    发明人： John G. Baust ,  Joshua T. Smith ,  Kimberly L. Santucci ,  Kristi K. Snyder ,  Anthony T. Robilotto ,  Robert G. Van Buskirk ,  John M. Baust ,  William L. Corwin ,  Jennie F. McKain

    IPC分类号： C12N5/00 ,  G01N33/50

    CPC分类号： C12M21/08 ,  C12M25/06 ,  C12M25/14 ,  C12M27/00 ,  C12M29/00 ,  C12N5/0062 ,  C12N5/0068 ,  C12N5/0697 ,  C12N2537/00 ,  G01N33/5008 ,  G01N33/5017

    摘要： A tissue engineered model (TEM) structure, an apparatus and method for making a TEM structure, and methods of using a TEM structure are disclosed. In an embodiment, the TEM structure includes at least one TEM segment. Each TEM segment includes a frame defining a bounded area, the frame having a height, a first edge, and a second edge opposite the first edge, each of the first edge and the second edge defining a perimeter of the bounded area, and the height defining a distance between the first edge and the second edge; a membrane affixed to the first edge about a perimeter of the frame; and a solidified gel and cell matrix disposed within the bounded area within the frame, wherein the solidified gel and cell matrix substantially fills a volume defined by the bounded area and the height of the frame.

    摘要翻译： 公开了一种组织工程模型（TEM）结构，用于制造TEM结构的装置和方法，以及使用TEM结构的方法。 在一个实施例中，TEM结构包括至少一个TEM段。 每个TEM段包括限定有界区域的框架，框架具有高度，第一边缘和与第一边缘相对的第二边缘，第一边缘和第二边缘中的每一个限定有界区域的周边，并且高度 限定所述第一边缘和所述第二边缘之间的距离; 围绕所述框架的周边固定到所述第一边缘的膜; 以及设置在框架内的有界区域内的凝固凝胶和细胞基质，其中凝固的凝胶和细胞基质基本上填充由界限区域和框架的高度限定的体积。